CROI (Conference on Retroviruses and Opportunistic Infections) Montreal, Canada Feb 8-11, 2009

Conference Reports for NATAP


16th CROI Conference on Retroviruses and Opportunistic Infections Montreal, Canada Feb 8-11, 2009

	NATAP Special Feature CROI: Summary Reports from 15 Clinicians Editor: Stephen Becker, MD Neurologic Complications of HIV Disease and Their Treatment - written by Scott L. Letendre, M.D. et al - (03/19/09) Antiretroviral agents that inhibit CCR5-utilizing HIV-1 - written by Eric S. Daar, M.D. (03/10/09) Inflammation, Cancers and Other Life Threats for People Living with HIV - written by David Alain Wohl, MD - (03/06/09) Bone/Osteoporosis CROI 2009 Update - written by Todd Brown, MD, PhD (03/04/09) Back to Basics: the science at CROI focuses the tough questions that remain in HIV pathogenesis, Part 2 (focal points for new therapies.) - written by David Margolis MD, University of North Carolina - (03/03/09) Back to Basics: the science at CROI focuses on the tough questions that remain in HIV pathogenesis - written by David Margolis, MD, University of North Carolina - (02/24/09) Summary of Antiretroviral Treatment Naïve Studies from CROI: Still Looking for a Consensus on When to Start - written by Susan J. Little, M.D. Associate Professor of Medicine University of California San Diego, USA - (02/27/09) - Clinical Pharmacology at CROI 2009: Pharmacoenhancement, Pharmacogenetics, Drug Interactions and the Pharmacotherapy of HIV Infection - written by Courtney V. Fletcher, Pharm.D. - (02/26/09) Pharmacology at the 2009 Conference on Retroviruses and Opportunistic Infections - written by Stephen Becker MD - (02/26/09) Forty-Fold Elevated Risk for Lymphoepithelial Carcinoma of Salivary Gland Among People with AIDS in the United States written by Kishor Bhatia, F Shebl, and E Engels NCI, NIH, Bethesda, MD, - (02/26/09) Update on Kidney Disease in HIV Infection: CROI 2009 - written by Christina M. Wyatt and Paul E. Klotman, Mt Sinai Hospital, New York City - (02/26/09) New HIV Agents - written by Joe Eron, MD, University of North Carolina - (02/25/09) Resistance Report - written by Mark A. Wainberg McGill University AIDS Centre, Montreal - (02/25/09) Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve outcome of Hepatitis coinfection in HIV-Infected Patients? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (02/24/09) Cardiovascular complications 16th CROI - written by Pablo Tebas, MD University of Pennsylvania - (02/24/09) Management of Treatment-Experienced Patients - written by Rafael E. Campo, MD University of Miami, Jackson Memorial Hospital (02/20/09) HIV Prevention at CROI 2009 - written by Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington (02/20/09) Unexpectedly high failure rate in LPV/r monotherapy arm, involving CNS, and association with low nadir CD4 count in the MOST study - (06/02/09) Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (06/02/09) Prevention of Rectal Simian HIV Transmission in Macaques by Intermittent Pre-exposure Prophylaxis with Oral Truvada - (04/17/09) Non-HIV Markers Add to HIV Signals in Predicting VA Cohort Deaths - written by Mark Mascolini - - (03/25/09) US and Canadian Studies Trace Impact of Resistance Results on Mortality - written by Mark Mascolini - - (03/25/09) Higher Rate of Non-AIDS Infection-Related Cancers With HIV May Be Waning in HAART Era - written by Mark Mascolini - (03/25/09) Mitochondrial DNA Levels in Pregnancy Are Not Decreased in ARV-treated Women Compared to HIV- Controls - (03/18/09) Raltegravir In Children and Adolescents: The French Expanded Access Program - (03/18/09) Prognosis of Non-Hodgkin's Lymphoma in HIV-infected Patients - (03/18/09) Influence of ART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin's Lymphoma: European Multi-Cohort Study, CD4 Predicts Non-Hodgkin's Lymphoma - (03/18/09) Effect of HIV Co-infection on the Outcome of Viral Cirrhosis Liver Transplant Candidates on the Waiting List at a Reference Center from 2001 to 2008 - (03/17/09) Liver Transplantation in 88 HIV-infected Patients - (03/17/09) HCV Causes Neurcognitive Impairment in HIV+ - (03/17/09) HCV Inflames the Brain in HIV Coinfected in Acute HCV - (03/17/09) Review of HIV+ Patient's Immunological Response Rate to High-dose HBV Re-vaccination Series: Cd4 & viral load predict response - (03/17/09) 5-Year Survival of HCV/HIV-co-infected Liver Transplant Recipients in Spain: A Case/Control Study - (03/17/09) Predictors of Chronic HBV Infection in HIV-infected Individuals: HAART Can Prevent Chronic HBV - (03/17/09) Interruption of ART and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in Strategies for Management of ART Viral Hepatitis-co-infected Participants and Matched Controls - (03/17/09) Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Co-infected Patients - (03/17/09) The Long-term Use of Tenofovir in HIV/HBV Co-infection Induces a Marked Decrease in Liver Fibrosis - (03/17/09) ART Reinitiation and HBV Rebound among HIV/HBV-co-infected Patients following ART Interruption in the Strategies for the Management of ART Study - (03/17/09) Association of Non-cirrhotic Portal Hypertension in HIV-infected Persons and ART with Didanosine - (03/17/09) Prolonged ART and Risk for Chronic Elevation of Alanine Aminotransferase in HIV-infected Persons without HBV or HCV Co-infections - (03/17/09) Incidence and Predictors of Acute Renal Failure in an Urban Cohort of Patients with HIV and Hepatitis C Co-infection - (03/17/09) High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART - (03/17/09) Progression of Liver Fibrosis in a Large Cohort of HIV Patients Over 4 Years: Emerging Contribution of Antiretrovirals and Metabolic Abnormalities - (03/17/09) Rosiglitazone Improves Lipoatrophy in Patients Receiving Thymidine-sparing Regimens - (03/16/09) Platelet Hyper-Reactivity in HIV-1-infected Patients on Abacavir-containing ART - (03/16/09) Association of Abacavir and HIV Disease Factors with Endothelial Function in Patients on Long-Term Suppressive Antiretroviral Therapy - (03/16/09) HIV in Semen Despite Undetectable in Blood: "residual risk of transmission is still possible during unprotected intercourse" - (03/16/09) Inflammatory Markers among Abacavir and non-Abacavir Recipients in the Womens' Interagency HIV Study and the Multicenter AIDS Cohort Study - (03/13/09) High-density Lipoprotein Particles but Not Low-density Lipoprotein Particles Predict Cardiovascular Disease Events in HIV Patients: Strategies for Management of ART Study - (03/13/09) Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples that Is Associated with Virological Outcome - (03/10/09) Association between Modifiable and Non-modifiable Risk Factors and Specific Causes of Death in the HAART Era: The Data Collection on Adverse Events of Anti-HIV Drugs Study -DAD Study - (03/09/09) Activation (Inflammation) and Coagulation Biomarkers are Independent Predictors for the Development of Opportunistic Disease in Patients with HIV Infection - (03/09/09) Biological Determinants of Immune Reconstitution following Long-term HAART: host factors & persistent gut microbial translocation drive chronic immune activation - (03/09/09) HIV+ Die More Quickly in FRAM & Low CD4 Predicts Death - (03/09/09) Osteopenia and Osteoporosis in HIV-infected Patients Are Associated with Reduced Frequency of Central Memory CD8+CD127+ T Cells: T-cell activation/senescence associated with bone loss - (03/05/09) Evidence of persistent low-level viremia in long-term HAART-suppressed individuals - (03/05/09) Brain Damage, Comorbidities and Early Death Threaten HIV+ - (03/05/09) Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study: boosted PI+TDF associated with renal function - (03/05/09) Viral Hepatitis is Associated with Reduced Bone Mineral Density in HIV-Infected Women but Not Men - (03/04/09) First Report of Dose/Response Data of HIV-infected Men Treated with Vitamin D3 Supplements - (03/04/09) Effects of Aging on HIV-1 Pathogenesis: HIV causes inflammation & T-cell activation, reported here to be more in postmenopausal women - (03/04/09) Raltegravir Intensification, Viral Replication, HIV Reservoirs & HAART - (03/04/09) Persisting High Prevalence of HIV Distal Sensory Peripheral Neuropathy in the Era of Combination ART: Correlates in the CHARTER Study - (03/04/09) Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome and Mortality during a Randomized Trial of Early versus Deferred ART in the Setting of Acute Opportunistic Infections (ACTG A5164) - (03/04/09) The Long Term Use of Tenofovir Disoproxil in HIV-HBV Co-Infection Induces a Marked Decrease in Liver Fibrosis - (03/04/09) Viro-Immunologic Abnormalities in Gut Associated Lymphoid Tissue Caused by Acute HIV Infection are not Reverted by Early Initiation of HAART - (03/04/09) Ongoing Viral Replication in the Gut Despite HAART Suppressive Viral Control: Lack of Compartmentalization of HIV HIV-1 Quasispecies and Circulation of CXCR4 using HIV-1 between Gut Associated Lymphoid Tissue (GALT) and the Peripheral Blood (PB) - (03/04/09) HIV-1 Induces Apoptosis in primary Osteoblasts: an Alternative Mechanism in the Osteopenia/Osteoporosis Development - (03/04/09) GENDER AND GONADAL FUNCTION DIFFERENCES IN THE PREVALENCE OF BONE MASS REDUCTION: higher rates of osteopenia and osteoporosis for men vs women and at early ages, in their 40s. - (03/04/09) Immune Senescence, Activation and Abnormal T cell Homeostasis Despite Effective HAART, A Hallmark of Early Aging in HIV Disease - (03/03/09) Changes in Bone Turnover, OPG/RANKL, and Inflammation with ART Initiation: A Comparison of Tenofovir- and Non-Tenofovir-Containing Regimens - (03/03/09) Evaluation of peripheral DEXA Bone Densitometry to identify low bone mineral density in HIV- infected men in UK: 60% osteopenia, 13% osteoporosis- median age 41 yrs; t-score/dexa predicts fracture in HIV - (03/03/09) Clinical Determinants of Bone Mineral Density (BMD) in Perinatally HIV-Infected Children - (03/03/09) HIV Drug Pipeline at CROI - (03/03/09) Bone Mineral Density in HIV+ Women: Relationship to Body Composition - (03/03/09) Preferential Bone Demineralization at the Hip in Treated HIV+ Males: Another Example of Premature Aging? - (03/03/09) Determinants (HIV, Cytokines) of Low Bone Density in Postmenopausal HIV+ Women - (03/03/09) Short term bone loss in HIV infected premenopausal women - (03/03/09) HIV-Associated Peripheral Neuropathy in the HAART Era: Results from AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Protocol A5001 - (03/02/09) Metabolic Syndrome, Diabetes, and Cognitive Impairment in the Era of Combination Antiretroviral Therapy - (03/02/09) HIGH FREQUENCY (50%) OF NEUROCOGNITIVE DISORDERS IN OLDER (>60 yrs) HIV-INFECTED PATIENTS DESPITE A SUSTAINED VIROLOGICAL AND IMMUNOLOGICAL RESPONSE ON CART: THE SIGMA STUDY - (03/02/09) Microbicide PRO 2000/0.5% Gel Shows Promise - (03/02/09) HBV Blippers and Rebounders under Treatment with Tenofovir in HIV/HBV Co-infection - (02/27/09) Aging with HIV - Lessons from CROI 2009 - Victor Valcour MD - (02/27/09) Cognitive Impairment & Neuropathy Persist Despite HAART and Are Associated With Metabolic Syndrome - (02/27/09) Phase 1, Single Ascending Oral Dose Study of the Safety, Tolerability, and Pharmacokinetics of MPC-9055 a Novel HIV-1 Maturation Inhibitor in HIV Negative Healthy Subjects - (02/27/09) Anti-viral Characterization in vitro of a Novel Maturation Inhibitor, MPC-9055 - (02/27/09) RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses - (02/27/09) In Vitro Resistance Selection Study and Favorable Human Pharmacokinetic Properties of RDEA427, a New HIV NNRTI - (02/27/09) Cervicovaginal Shedding of HIV-1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota - (02/26/09) Impairment in Kidney Tubular Function in Patients Receiving Tenofovir Is Associated with Higher Plasma Tenofovir Levels - (02/26/09) HIV & HAART Interruption Increase Inflammation and Disease - (02/26/09) Weekly and Biweekly Subcutaneous PRO 140 Demonstrates Potent, Sustained Antiviral Activity: 2-week study - (02/26/09) Lopinavir/ritonavir+Tenofovir/Emtricitabine Is Superior to Nevirapine+Tenofovir/Emtricitabine for Women with prior Exposure to Single-dose Nevirapine: A5208 ("OCTANE") - (02/25/09) No Association of Abacavir (ABC) Use with Risk of Myocardial Infarction (MI) or Severe Cardiovascular Disease Events (SCVD): Results from ACTG A5001/ALLRT - (02/25/09) Progression of High-grade Anal Intraepithelial Neoplasia to Invasive Anal Cancer among HIV+ Men Who Have Sex with Men - (02/25/09) Prevalence of Cervical Cancer Screening Among HIV-Infected Women in the United States: 23% Did Not Receive Pap tests within last year - (02/25/09) Serious Fatal and Non-fatal Non-AIDS-defining Illnesses in Europe: most common no-AIDS events malignancies/CVD/liver in EuroSida - (02/25/09) Causes of Death in Patients Treated with ART (IDUs vs non-IDUs), 1996 to 2006: Collaborative Analysis of 13 Cohort Studies - (02/25/09) Relationship between Current Level of Immunodeficiency and Non-AIDS-defining Malignancies, EuroSida: "Immunosuppression ...current CD4 count....was associated with an excess risk of NADM" - (02/25/09) Infection-related Non-AIDS-defining Cancer Risk in HIV-infected and -uninfected Persons: Increased Rates in HIV+ vs HIV-negatives in Kaiser - (02/25/09) New HIV Drug Candidates in Pre-Clinical Development - (02/24/09) A Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OBP-601, a Novel NRTI, in Healthy Subjects - (02/24/09) CMX157 Conjugate of tenofovir, prodrug: Hexadecyloxypropyl Tenofovir Associates Directly with HIV and Subsequently Inhibits Viral Replication in Untreated Cells - (02/24/09) Inhibitors of the RNase H Activity of Reverse Transcriptase as an Approach to New HIV-1 Antiretroviral Agents: Merck program - (02/24/09) High HCV viral load Is Associated with an Increased Risk for Mortality in HIV/HCV-co-infected Individuals - (02/24/09) A Pilot Study to Determine the Effect on Dyslipidemia of the Addition of Tenofovir to Stable ART in HIV-infected Subjects: Results from A5206 Study Team v - (02/24/09) Single Dose Tenofovir Disoproxil Fumarate (TDF) with and without Emtricitabine (FTC) in HIV-1 Infected Pregnant Women and Their Infants: Pharmacokinetics (PK) and Safety - - (02/24/09) HIV Infection May Make the Brain 15 to 20 Years Older: HIV slows cerebral blood flow and stimulus response in MRI study - written by Mark Mascolini - (02/23/09) Framingham Risk Score Linked to Other Heart Risk Factors in HIV Cohort - written by Mark Mascolini - (02/23/09) No Residual Raltegravir Activity After Resistance Emerges - written by Mark Mascolini - (02/23/09) Effects of Aging on HIV Pathogenesis: aging is associated with higher t-cell activation in women than men, effects of menopause on inflammation and immune activation...." (02/23/09) Bone Loss at Baseline and Week 144 in Study 903 TDF vs d4T + EFV (02/23/09) Safety and Efficacy of Raltegravir (RAL) in Pediatric HIV Infection. Preliminary Analysis From IMPAACT P1066 (02/23/09) Telbivudine Has Activity against HIV (02/23/09) Abacavir Use is Not Associated with Lack of Virologic Response in ARV-treated HIV/HCV-Coinfected Patients Receiving PEG-IFN and Ribavirin (02/23/09) Telbivudine Has No In Vitro Activity Against Laboratory and Clinical HIV-1, Including 5 Clades and Drug Resistant Clinical Isolates (02/23/09) Heart Disease Marker Rises in Women During 96 Weeks of Suppressive Efavirenz - written by Mark Mascolini - (02/20/09) Liver Fibrosis Marker Rises in SMART Interrupters and Predicts Non-AIDS Deaths - written by Mark Mascolini - (02/20/09) Diverse Disease Markers Up in SMART Patients Regardless of Antiretroviral Therapy: inflammation markers linked to death, ART interruption, HIV, aging, & ART - written by Mark Mascolini - (02/20/09) Immune Activators Stay High Despite Long-Term HIV Suppression With Antiretrovirals: affects CD4 recovery - written by Mark Mascolini - (02/20/09) Pharmacokinetics and Safety of Twice Daily Atazanavir 300 mg and Raltegravir 400 mg in Healthy Subjects - (02/20/09) Epidemic of Acute HCV Among MSM in Europe and New York City - (02/20/09) Neurocognitive Disorders Threaten HIV+ - (02/20/09) Immune Senescence, Activation, and Abnormal T Cell Homeostasis despite Effective HAART, a Hallmark of Early Aging in HIV Disease: "HIV-infected subjects (median 56 years) with good immune reconstitution and viral suppression had immune changes comparable to older (median 88 years) HIV-negative subjects" - (02/20/09) High Prevalence of Hepatic Fibrosis and Steatosis in HIV/AIDS Patients without Chronic Viral Hepatitis but with Chronically Elevated Transaminases on ART: 35% without HCV or HBV had significant liver disease - (02/20/09) CCR5-tropic Resistance to Maraviroc is Uncommon Even Among Patients on Functional MVC Monotherapy or with Ongoing Low-level Replication - (02/20/09) New HIV Drugs: NNRTI, PRO140, Maturation (02/19/09) Markers of Inflammation, Coagulation and Renal Function in HIV-infected Adults in SMART and in two Large Population-Based Studies, CARDIA and MESA: HIV+ have higher levels of inflammatory markers on and off HAART, "markers appear to predict mortality & disease progression in HIV" (02/19/09) No Association of Abacavir Use with Risk of Myocardial Infarction or Severe Cardiovascular Disease Events: Results from ACTG A5001 (02/19/09) Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naive HIV-Infected Patients (02/19/09) Factors affecting virologic response to darunavir/ritonavir and lopinavir/ritonavir in treatment-naive HIV-1-infected patients in ARTEMIS at 96 weeks (02/19/09) Characterization of virologic failures in the randomized, controlled, Phase III ARTEMIS trial in treatment-naive patients (Week 96 analysis) (02/19/09) Emerging Patterns of Resistance to Integrase Inhibitors (02/19/09) Assessment of Renal Findings of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study (02/19/09) Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) in the HEAT Study (02/19/09) Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study (02/19/09) HIV-1 INFECTION IS ASSOCIATED WITH ACCELERATED VASCULAR AGING (02/18/09) SIMPLIFICATION WITH FIXED-DOSE TENOFOVIR-EMTRICITABINE OR ABACAVIR-LAMIVUDINE IN ADULTS WITH SUPPRESSED HIV REPLICATION (THE STEAL STUDY): A RANDOMIZED, OPEN-LABEL, 96-WEEK, NON-INFERIORITY TRIAL (02/18/09) Neurocognitive (and neuropathy) Impairment Rate Remains High in Diverse US Cohort - written by Mark Mascolini - (02/18/09) Antiretrovirals Have Not Banished Brain Injury in 7-Center US Imaging Study: brain damage persists despite HAART- inflammation and neuronal damage - written by Mark Mascolini - (02/18/09) HCV Independently Adds to Hospital, Emergency Room, and Disability Days With HIV: days in hospital doubled - written by Mark Mascolini - (02/18/09) Suspending Antiretrovirals Has Fast Negative Impact on HDL Particle Concentrations: interruptions reduce HDL and this predicts risk for cardiovascular disease in SMART - written by Mark Mascolini - (02/18/09) First Double-Blind HIV+ Trial of Ezetimibe Plus Statin Finds Falling LDL Cholesterol - written by Mark Mascolini - (02/18/09) Endothelial Function, Inflammatory Markers Do Not Change 24 Weeks After Switch to Atazanavir - written by Mark Mascolini - (02/18/09) Two Inflammation Markers (hsCRP & IL-6) Predict Higher Risk of Opportunistic Disease in SMART - written by Mark Mascolini - (02/18/09) Platelet Function & Heart Attacks in HIV+ & ART (02/17/09) Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive (02/17/09) HIV Progression Not Affected by Hormonal Contraception in Africa Study (02/17/09) The Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-naive Patients Through Seven Years (02/17/09) HIV, Cancer and Immunity (02/17/09) HIV Sometimes Detectable in Semen When Undetectable in Blood - written by Mark Mascolini - (02/17/09) Low-Level HIV in CSF When HIV-RNA is < 50 Tied to Type of ART and Worse Cognitive Function - written by Mark Mascolini - (02/13/09) Multicohort D:A:D Study Pinpoints Non-HIV Death Risk Factors People Can Change - written by Mark Mascolini - (02/13/09) Helping HIV Patients Stop Smoking--Worthy Goal But Tough Work - written by Mark Mascolini - (02/13/09) HIV Has as Much Impact on Heart Health as Traditional Risk Factors - written by Mark Mascolini - (02/13/09) K103N and Efavirenz vs Nevirapine Tied to Better Response to Etravirine - written by Mark Mascolini - (02/13/09) Preclinical and Early Clinical Evaluation of SPI-452, a New Pharmacokinetic Enhancer (PKE) - (02/12/09) Review of Cancer Incidence in Raltegravir (RAL) Clinical Trials - (02/12/09) 96-Week Results from BENCHMRK 1&2, Phase III Studies of Raltegravir (RAL) in Patients (pts) Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV - (02/12/09) Abacavir - (02/12/09) 3 Studies on Abacavir & MI Risk: French Cohort, D.A.D. (slides), ALLRT with 2 Different Results - (02/12/09) Switch to Raltegravir From Lopinavir in Highly Treatment-Experienced Patient Group: SWITCHMRK 1 & 2 Studies - written by Mark Mascolini - (02/12/09) Replacing Enfuvirtide With Raltegravir in France - written by Mark Mascolini - (02/12/09) Lower CD4 Count Linked to Non-AIDS Cancers in EuroSIDA Study - written by Mark Mascolini - (02/12/09) Risk of non-Hodgkin Lymphoma Death Still Higher With HIV Infection - written by Mark Mascolini - (02/12/09) Extra CD4s With IL-2 Confer No Clinical Benefit in Two Randomized Trials - written by Mark Mascolini - (02/12/09) High HCV Load Doubles the Death Risk in People Coinfected With HIV - written by Mark Mascolini - (02/12/09) Peginterferon (Pegasys) and Weight-Based Ribavirin for 72 Weeks in HIV+ Early Responders - written by Mark Mascolini - (02/12/09) MI Rates Converge in California Health System Groups With and Without HIV: trend down in HIV+ - written by Mark Mascolini - (02/12/09) Non-AIDS Illness More Common Than AIDS--and More Deadly--in EuroSIDA - written by Mark Mascolini - (02/12/09) French Hospital Study and Further D:A:D Analyses Suggest MI Risk With Abacavir - written by Mark Mascolini - (02/12/09) GS-9350: A Pharmacoenhancer Without anti-HIV Activity - (02/11/09) Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350 - (02/11/09) Complete Protection against Repeated Vaginal Simian HIV Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine - (02/11/09) Switching from Stable Lopinavir/Ritonavir (LPV/r)-Based to Raltegravir (RAL)-Based Combination Antiretroviral Therapy (ART) Resulted In a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 (SWITCHMRK) - (02/11/09) Smoking Emerges as Top Death Risk Factor in FRAM Participants With HIV - written by Mark Mascolini - (02/11/09) HIV and Diabetes/Hyperlipidemia Cause Kidney Decline - written by Mark Mascolini - (02/11/09) World Health Organization CD4 Criteria Fall Far Short in Predicting Antiretroviral Failure - written by Mark Mascolini - (02/10/09)